Benign Prostatic Hyperplasia Devices Market Insight

DelveInsight’s ‘Benign Prostatic Hyperplasia Devices- Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Benign Prostatic Hyperplasia Devices and the historical and forecasted Benign Prostatic Hyperplasia Devices market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.


The Benign Prostatic Hyperplasia Devices (BPH) market report provides an overview of Benign Prostatic Hyperplasia Devices, treatment including detailed chapters on types of devices. Additionally, the report provides insight on the BPH market share of the individual BPH devices, current and forecasted BPH market size from 2018 to 2026 segmented by seven major markets. The report also covers the market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Benign Prostatic Hyperplasia Devices Understanding

Benign Prostatic Hyperplasia Devices (BPH) Overview

Benign Prostatic Hyperplasia Devices (BPH), also known as prostate gland enlargement is a common condition in men as they get older. As the prostate enlarges, it presses against the urethra. The bladder wall becomes thicker and weak, ultimately lose the ability to empty completely. This leads to urine retention. The BPH is benign and non-cancerous. The cause of BPH is not clear. However, Aging and a family history of BPH increase a man’s risk for BPH. Obesity, lack of staying active, and erectile dysfunction can also increase risk.


The prostate goes through two main growth periods as a man ages. The first occurs early in puberty when the prostate doubles in size. The second phase of growth begins around age 25 and continues during most of a man’s life. BPH often occurs with the second growth phase. The condition can be treated by various methods which include prescribed drugs, minimally invasive and invasive surgeries.


COVID-19 impacted the Benign Prostatic Hyperplasia Devices market heavily in 2020 and its impact will be seen in the following up years. This is because BPH was positioned as one of the lowest priorities of non-oncological procedures. According to one research, 80% of the surveyed urologists postponed BPH procedures until the pandemic is over leading to the cancellation of more than 2.5 million urological benign surgeries during the peak of disruption by COVID-19.

Geography Covered

  • The US
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2018–2026

List of Companies:

  • Olympus Corporation
  • Butterfly Medical
  • Teleflex Incorporated
  • SRS Medical
  • Urotronic
  • Zenflow
  • ProArc medical
  • Medion Biodesign

More companies in the report…

Benign Prostatic Hyperplasia Devices- Competitive Analysis

This segment of the report provides a brief competitive analysis of Benign Prostatic Hyperplasia Devices to help understand the competition in the market. It gives a comparative understanding of the products based on parameters such as type of regulatory approval.

Benign Prostatic Hyperplasia Devices: Market Segmentation

By Treatment Type-

  • Pharmacological
  • Surgery
  • Medical Devices


By Medical Device-

  • UroLift System
  • Butterfly Devices
  • Spanner Temporary Prostatic Stent
  • iTIND
  • Optilume™ BPH Prostatic DCB Dilation Catheter
  • ClearRing™ system


Benign Prostatic Hyperplasia Devices: Eligible Patient Population

This segment of the report provides an analysis of the eligible patient pool that incorporate Benign Prostatic Hyperplasia Devices for their treatment, across 7MM during the study period (2018 and 2026).

Benign Prostatic Hyperplasia Devices: Market Analysis

This segment illustrates the market of Benign Prostatic Hyperplasia Devices across 7MM and how the market is expected to rise in the study period (2018 to 2026), at a CAGR of XX%.


Benign Prostatic Hyperplasia Devices: Market Drivers and Barriers

The report provides insights into the market driving factors and the barriers shaping the Benign Prostatic Hyperplasia Devices market.


Market Drivers:

  • Increase in the elderly male population
  • Increase in incidence and prevalence of BPH and LUTS
  • Technological advancements in minimally invasive products
  • Favorable reimbursement policies
  • Partnerships as a part of the growth strategy


Market Barriers:

  • Lack of awareness
  • Lack of skilled and trained professionals
  • Availability of alternative products
  • Adverse events and product recalls

KOL- Views

To keep up with the market trends, we take KOLs and SME’s opinion working in Benign Prostatic Hyperplasia Devices domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or SHD Devices market trend. This will support the clients in making informed business decisions by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

  • The report covers the descriptive overview of Benign Prostatic Hyperplasia Devices explaining its applications, advantages, and limitations, etc.
  • Additionally, an all-inclusive account of the currently available Benign Prostatic Hyperplasia Devices is provided, which will have an impact on the future market of Benign Prostatic Hyperplasia Devices.
  • A detailed review of Benign Prostatic Hyperplasia Devices market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Benign Prostatic Hyperplasia Devices market.

Report Highlights

  • The report covers descriptive overview of Benign Prostatic Hyperplasia Devices and application, including detailed chapters on type of products.
  • The report provides an insight into the patient population eligible for Benign Prostatic Hyperplasia Devices in the 7MM, covering the US, EU5 (Germany, Spain, France, Italy, UK) & Japan.
  • The report is a comprehensive account of marketed devices present in the Benign Prostatic Hyperplasia Devices market.
  • The report also reviews the detailed global historical and forecasted Benign Prostatic Hyperplasia Devices market including assessing the outreach in 7MM.
  • The report helps in developing business strategies by understanding trends shaping and driving the global Benign Prostatic Hyperplasia Devices market.

Benign Prostatic Hyperplasia Devices Report Key Strengths

  • 6 Years Forecast
  • 7MM Coverage 
  • Competitive Landscape
  • Patient pool
  • Market Size

Benign Prostatic Hyperplasia Devices Report Assessment

  • Marketed Product profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
  • Market Forecast
  • KOL’S views

Key Questions

Market Insights:

  • What was the Benign Prostatic Hyperplasia Devices market share (%) distribution in 2018 and how it will look like in 2026?
  • What will be the Benign Prostatic Hyperplasia Devices total market Size as well as market Size by devices across the 7MM during the forecast period (2018–2026)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Benign Prostatic Hyperplasia Devices Market Size during the forecast period (2018–2026)?
  • At what CAGR, the Benign Prostatic Hyperplasia Devices market is expected to grow in 7MM during the forecast period (2018–2026)?
  • What will be the Benign Prostatic Hyperplasia Devices market outlook across the 7MM during the forecast period (2018–2026)?
  • What will be the Benign Prostatic Hyperplasia Devices market growth till 2026 and what will be the resultant market size in the year 2026?
  • How will the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?


Competitive Landscape:

  • What are the current devices available in the Benign Prostatic Hyperplasia Devices market?
  • What is the Benign Prostatic Hyperplasia Devices available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?
  • How many key players are developing Benign Prostatic Hyperplasia Devices?
  • What are the key collaborations (Industry–Industry), Mergers and acquisitions, licensing activities related to the Benign Prostatic Hyperplasia Devices?
  • What are the key designations that have been granted for the current Benign Prostatic Hyperplasia Devices?
  • What are the 7MM historical and forecasted market of Benign Prostatic Hyperplasia Devices?

 

Frequently Asked Questions

What is Benign Prostatic Hyperplasia Devices?

Benign Prostatic Hyperplasia Devices (BPH), also known as prostate gland enlargement is a common condition in men as they get older. As the prostate enlarges, it presses against the urethra.


How is Benign Prostatic Hyperplasia Devices Market Segmented?

The Benign Prostatic Hyperplasia Devices is segmented on the basis of By Treatment Type, and by Medical Device Type.


Who are the leading companies in Benign Prostatic Hyperplasia Devices Market Landscape?

The leading companies that are working in the Benign Prostatic Hyperplasia Devices Market are Olympus Corporation, Butterfly Medical, Teleflex Incorporated, SRS Medical, Urotronic, Zenflow, ProArc medical, Medion Biodesign and many others.


What are the Benign Prostatic Hyperplasia Devices Market Drivers?

The market driver is the increase in the elderly male population, increase in incidence and prevalence of BPH and LUTS, technological advancements in minimally invasive products, and favourable reimbursement policies, partnerships as a part of the growth strategy.


What are the Benign Prostatic Hyperplasia Devices Market Barriers?

The market barrier is the Lack of awareness, lack of skilled and trained professionals, and availability of alternative products, and adverse events and product recalls.


What are the key strengths of Benign Prostatic Hyperplasia Devices Market Report?

Key strengths of Benign Prostatic Hyperplasia Devices Market Report are 6 Years Forecast, 7MM Coverage, Competitive Landscape, PEST Analysis, Market Size, Market Drivers and Market Barriers.


What is the Impact of COVID-19 on Benign Prostatic Hyperplasia Devices Market?

The Benign Prostatic Hyperplasia Devices Market had observed a positive shift in market revenues due to the COVID 19 in 2020. The report includes the factors that are contributing to this significant increase in detail.

1 Key Insights

2 Report Introduction

3 Executive Summary Of Benign Prostatic Hyperplasia

4 Benign Prostatic Hyperplasia (Bph): Background And

Overview

4.1 Introduction

4.2 Etiology Of Benign Prostatic Hyperplasia

4.3 Pathology

4.4 Symptoms

4.5 Diagnosis

4.6 Treatments

4.6.1 Herbal Supplements

4.6.2 Pharmacological

4.6.3 Surgical Interventions

4.6.4 Medical Device

4.7 Complications Associated With Benign Prostatic Enlargement

5 Benign Prostatic Hyperplasia: Regulatory Approval And Reimbursement Scenario

5.1 Benign Prostatic Hyperplasia Devices: Regulatory Approval

5.1.1 United States Regulation Of Benign Prostatic Hyperplasia Devices

5.1.2 European Regulation Of Benign Prostatic Hyperplasia Devices

5.1.3 Japan Regulation Of Benign Prostatic Hyperplasia Devices

5.2 Benign Prostatic Hyperplasia Devices:Reimbursement Scenario

5.2.1 Reimbursement Scenario In The United States

5.2.2 Reimbursement Scenario In Europe

5.2.3 Reimbursement Scenario In Japan

6 Benign Prostatic Hyperplasia: Marketed Products

6.1 Key Cross Competition Of Marketed Benign Prostatic Hyperplasia Medical Devices Based On Their Approval

6.2 Company And Product Profiles

6.2.1 Olympus Corporation

6.2.2 Butterfly Medical

6.2.3 Teleflex Incorporated

6.2.4 Srs Medical

6.2.5 Urotronic

7 Benign Prostatic Hyperplasia: Emerging Devices

7.1 Zenflow

7.2 Proarc Medical

7.3 Medion Biodesign

8 Assumptions And Rationale For Epidemiology And Market

Size Estimation

9 Epidemiology And Patient Population

9.1 Key Findings

9.2 7mm Total Diagnosed Prevalent Patient Population Of Benign Prostate Hyperplasia

9.3 Age-Specific Prevalence Of Benign Prostate Hyperplasia In The United States

9.4 Treatable Cases Of Benign Prostate Hyperplasia In The United States

10 Country-Wise Epidemiology

10.1 The United States

10.1.1 Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In The United States

10.1.2 Age-Specific Prevalence Of Benign Prostate Hyperplasia In The United States

10.1.3 Treatable Cases Of Benign Prostate Hyperplasia In The United States

10.2 Eu5

10.2.1 Germany

10.2.2 France

10.2.3 Italy

10.2.4 Spain

10.2.5 United Kingdom

10.3 Japan

10.3.1 Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Japan

10.3.2 Age-Specific Prevalence Of Benign Prostate Hyperplasia In Japan

10.3.3 Treatable Cases Of Benign Prostate Hyperplasia In Japan

11 Benign Prostatic Hyperplasia: Market Analysis

11.1 Benign Prostatic Hyperplasia Market Size In The 7mm

11.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In The 7mm

12 Country-Wise Market Size Of Benign Prostatic

Hyperplasia

12.1 United States

12.1.1 Benign Prostatic Hyperplasia Market Size In The United States

12.1.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In The United States

12.2 Germany

12.2.1 Benign Prostatic Hyperplasia Market Size In Germany

12.2.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In Germany

12.3 France

12.3.1 Benign Prostatic Hyperplasia Market Size In France

12.3.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In France

12.4 Italy

12.4.1 Benign Prostatic Hyperplasia Market Size In Italy

12.4.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In Italy

12.5 Spain

12.5.1 Benign Prostatic Hyperplasia Market Size In Spain

12.5.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In Spain

12.6 United Kingdom

12.6.1 Benign Prostatic Hyperplasia Market Size In United Kingdom

12.6.2 Benign Prostatic Hyperplasia Market Share By Medical Devices In United Kingdom

12.7 Japan

12.7.1 Benign Prostatic Hyperplasia Market Size In Japan

12.7.3 Benign Prostatic Hyperplasia Market Share By Medical Devices In Japan

13 Patient Journey

14 Case Study: Medical Devices

15 Supporting Associations

16 Kol’s Views

17 Market Drivers

18 Market Barriers

19 Unmet Needs

20 Pest Analysis

21 Appendix

21.1 Bibliography

21.2 Report Methodology

22 Delveinsight Capabilities

23 Disclaimer

24 About Delveinsight

List of Table

Table 1: Summary Of Benign Prostatic Hyperplasia, Market, Eligible Patient Pool, And Key Events (2018–2026)

Table 2: American Urological Association Symptom Index To Assess The Severity Of Benign Prostatic Hyperplasia (Bph)

Table 3: Pharmacologic Treatment Options For Bph

Table 4: Reimbursement Coverage For Bph Treatments In The Us

Table 5: Assessment Based On Stage

Table 6: Bph Devices

Table 7: Company Profile: Olympus Corporation

Table 8: Company Profile: Butterfly Medical

Table 9: Company Profile: Teleflex Incorporated

Table 10: Company Profile: Srs Medical

Table 11: Company Profile: Urotronic

Table 12: Emerging Benign Prostatic Hyperplasia Devices

Table 13: Company Profile: Zenflow

Table 14: Company Profile: Proarc Medical

Table 15: Company Profile: Medion Biodesign

Table 16: Diagnosed Prevalent Patient Population Of Benign Prostate Hyperplasia In 7mm (2018–2026)

Table 17: Age-Specific Prevalence Of Benign Prostate Hyperplasia In 7mm (2018–2026)

Table 18: Treatable Cases Of Benign Prostate Hyperplasia In 7mm (2018–2026)

Table 19: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In The United States (2018–2026)

Table 20: Age-Specific Prevalence Of Benign Prostate Hyperplasia In The United States (2018–2026)

Table 21: Treatable Cases Of Benign Prostate Hyperplasia In The United States(2018–2026)

Table 22: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Germany (2018–2026)

Table 23: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Germany (2018–2026)

Table 24: Treatable Cases Of Benign Prostate Hyperplasia In Germany (2018–2026)

Table 25: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In France (2018–2026)

Table 26: Age-Specific Prevalence Of Benign Prostate Hyperplasia In France (2018–2026)

Table 27: Treatable Cases Of Benign Prostate Hyperplasia In France (2018–2026)

Table 28: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Italy (2018–2026)

Table 29: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Italy (2018–2026)

Table 30: Treatable Cases Of Benign Prostate Hyperplasia In Italy (2018–2026)

Table 31: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Spain (2018–2026)

Table 32: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Spain (2018–2026)

Table 33: Treatable Cases Of Benign Prostate Hyperplasia In Spain (2018–2026)

Table 34: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In United Kingdom (2018–2026)

Table 35: Age-Specific Prevalence Of Benign Prostate Hyperplasia In United Kingdom (2018–2026)

Table 36: Treatable Cases Of Benign Prostate Hyperplasia In United Kingdom (2018–2026)

Table 37: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Japan (2018–2026)

Table 38: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Japan (2018–2026)

Table 39: Treatable Cases Of Benign Prostate Hyperplasia In Japan (2018–2026)

Table 40: Market Size Of Benign Prostatic Hyperplasia In The 7mm In Usd Million (2018–2026)

Table 41: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In The 7mm In Usd Million (2018–2026)

Table 42: Market Size Of Benign Prostatic Hyperplasia In The United States In Usd Million (2018–2026)

Table 43: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In The United States In Usd Million (2018–2026)

Table 44: Market Size Of Benign Prostatic Hyperplasia In Germany In Usd Million (2018–2026)

Table 45: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Germany In Usd Million (2018–2026)

Table 46: Market Size Of Benign Prostatic Hyperplasia In France In Usd Million (2018-2026)

Table 47: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In France In Usd Million (2018–2026)

Table 48: Market Size Of Benign Prostatic Hyperplasia In Italy In Usd Million (2018–2026)

Table 49: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Italy In Usd Million (2018–2026)

Table 50: Market Size Of Benign Prostatic Hyperplasia In Spain In Usd Million (2018-2026)

Table 51: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Spain In Usd Million (2018–2026)

Table 52: Market Size Of Benign Prostatic Hyperplasia In The United Kingdom In Usd Million (2018-2026)

Table 53: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In United Kingdom In Usd Million (2018–2026)

Table 54: Market Size Of Benign Prostatic Hyperplasia In Japan In Usd Million (2018-2026)

Table 55: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Japan In Usd Million (2018–2026)

List of Figures

Figure 1: Development Of Bph

Figure 2: Growth Factors Responsible For Benign Prostatic Hyperplasia

Figure 3: Sagittal And Coronal Section Of The Prostate

Figure 4: Signs And Symptoms Of Benign Prostatic Hyperplasia

Figure 5: Digital Rectal Exam

Figure 6: Diagnosis Of Benign Prostatic Hyperplasia (Bph)

Figure 7: Greenlight Xps™ Laser Therapy System

Figure 8: Rezūm System

Figure 9: Class Ii Device Approval Processes In The United States

Figure 10: Class Iii Device Approval Processes In The United States

Figure 11: Approval Processes In European Countries

Figure 12: Class Ii Device Approval Processes In Japan

Figure 13: Class Iii Device Approval Processes In Japan

Figure 14: Healthcare Reimbursement System In The Us

Figure 15: Key Cross Competition Of The Marketed Benign Prostatic Hyperplasia Devices On The Basis Of Approval

Figure 16: Company Revenue

Figure 17: R&D Expenses

Figure 18: The Itind Device

Figure 19: The Butterfly Medical Device

Figure 20: Company Revenue

Figure 21: R&D Expenses

Figure 22: The Urolift System

Figure 23: Spanner Prostate Stent

Figure 24: Optilume Bph Prostatic Dcb Dilation Catheter

Figure 25: Zenflow Spring® Implant

Figure 26: Diagnosed Prevalent Patient Population Of Benign Prostate Hyperplasia In 7mm (2018–2026)

Figure 27: Age-Specific Prevalence Of Benign Prostate Hyperplasia In 7mm (2018–2026)

Figure 28: Treatable Cases Of Benign Prostate Hyperplasia In 7mm (2018–2026)

Figure 29: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In The United States (2018–2026)

Figure 30: Age-Specific Prevalence Of Benign Prostate Hyperplasia In The United States (2018–2026)

Figure 31: Treatable Cases Of Benign Prostate Hyperplasia In The United States (2018–2026)

Figure 32: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Germany (2018–2026)

Figure 33: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Germany (2018–2026)

Figure 34: Treatable Cases Of Benign Prostate Hyperplasia In Germany (2018–2026)

Figure 35: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In France (2018–2026)

Figure 36: Age-Specific Prevalence Of Benign Prostate Hyperplasia In France (2018–2026)

Figure 37: Treatable Cases Of Benign Prostate Hyperplasia In France (2018–2026)

Figure 38: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Italy (2018–2026)

Figure 39: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Italy (2018–2026)

Figure 40: Treatable Cases Of Benign Prostate Hyperplasia In Italy (2018–2026)

Figure 41: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Spain (2018–2026)

Figure 42: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Spain (2018–2026)

Figure 43: Treatable Cases Of Benign Prostate Hyperplasia In Spain (2018–2026)

Figure 44: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In United Kingdom (2018–2026)

Figure 45: Age-Specific Prevalence Of Benign Prostate Hyperplasia In United Kingdom (2018–2026)

Figure 46: Treatable Cases Of Benign Prostate Hyperplasia In United Kingdom (2018–2026)

Figure 47: Diagnosed Prevalent Cases Of Benign Prostate Hyperplasia In Japan (2018–2026)

Figure 48: Age-Specific Prevalence Of Benign Prostate Hyperplasia In Japan (2018–2026)

Figure 49: Treatable Cases Of Benign Prostate Hyperplasia In Japan (2018–2026)

Figure 50: Market Size Of Benign Prostatic Hyperplasia In The 7mm In Usd Million (2018–2026)

Figure 51: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In The 7mm In Usd Million (2018–2026)

Figure 52: Market Size Of Benign Prostatic Hyperplasia In The United States In Usd Million (2018-2026)

Figure 53: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In The United States In Usd Million (2018–2026)

Figure 54: Market Size Of Benign Prostatic Hyperplasia In Germany In Usd Million (2018-2026)

Figure 55: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Germany In Usd Million (2018–2026)

Figure 56: Market Size Of Benign Prostatic Hyperplasia In France In Usd Million (2018–2026)

Figure 57: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In France In Usd Million (2018–2026)

Figure 58: Market Size Of Benign Prostatic Hyperplasia In Italy In Usd Million (2018-2026)

Figure 59: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Italy In Usd Million (2018–2026)

Figure 60: Market Size Of Benign Prostatic Hyperplasia In Spain In Usd Million (2018–2026)

Figure 61: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Spain In Usd Million (2018–2026)

Figure 62: Market Size Of Benign Prostatic Hyperplasia In The United Kingdom In Usd Million (2018-2026)

Figure 63: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In United Kingdom In Usd Million (2018–2026)

Figure 64: Market Size Of Benign Prostatic Hyperplasia In Japan In Usd Million (2018-2026)

Figure 65: Market Share Of Benign Prostatic Hyperplasia By Medical Devices In Japan In Usd Million (2018–2026)

• Olympus Corporation

• Butterfly Medical

• Teleflex Incorporated

• SRS Medical

• Urotronic

• Zenflow

• ProArc medical

• Medion Biodesign

  • Tags:
  • Benign Prostatic Hyperplasia Device...
  • Benign Prostatic Hyperplasia Devic...
  • Benign Prostatic Hyperplasia Devic...
  • Benign Prostatic Hyperplasia Medic...
  • Benign Prostatic Hyperplasia Devic...
  • Benign Prostatic Hyperplasia Devic...
  • Benign Prostatic Hyperplasia Devic...
  • Benign Prostatic Hyperplasia Marke...
  • Benign Prostatic Hyperplasia Compa...
  • Benign Prostatic Hyperplasia devic...

Forward to Friend

Need A Quote